Abstract For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients with metastatic bladder cancer. We conducted a systematic review according to the PRISMA statement for data published on the clinical efficacy of checkpoint inhibitors in metastatic bladder cancer. Clinical efficacy of anti PD-L1 therapy was investigated in prospective trials in a total of 155 patients. Patients with positive expression for PD-L1 tended towards better overall response rates (ORR) compared to those with negative expression (34/76 vs 10/73, 45 vs 14 %; p = 0.21). Among patients with PD-L1 positive tumors, those with non-visceral metastases exhibited significantly higher ORR compared to those with visceral metastases (82 vs 28 %; p = 0.001). For anti-CTLA4 therapy, there were no data retrievable on clinical efficacy. Although data on clinical efficacy of checkpoint inhibitors in metastatic bladder cancer are currently limited, the efficacy of these drugs might depend mainly on the metastatic volume and immune system integrity. Patients with PD-L1 positive tumors and non-visceral metastases seem to derive the highest benefit from therapy.
Introduction
Bladder cancer is one of the common lethal malignancies worldwide with poor outcomes for patients with advanced stages [1] [2] [3] . Indeed, curability of patients with locally advanced or distant metastatic disease is rarely possible. Despite advances in cancer therapy the 5-year survival rates of locally advanced and metastatic bladder cancer range only at 33 and 5 % respectively [4] . Cisplatin-based combination chemotherapy is used for adjuvant treatment of locally advanced tumors [5] and combination of gemcitabine and cisplatin is the standard first-line therapy for metastatic bladder cancer. It increases the median survival from 6 to 14 months compared to best supportive care [6] .
Owing to differences in the antigenicity between healthy and malignant tissue, tumor cells are constantly under attack by immune cells [7] . However, this activity can be silenced through different ways. Self-immune tolerance to prevent autoimmune activity limits anti-tumor action. In addition, tumors are capable of circumventing the antitumor response via various immune-escape mechanisms [8] . Based on the immunogenic properties of some solid tumors, immunotherapy was launched as one of the treatment modalities in cancer therapy many decades ago [9] . One of the hallmarks of cancer development is the ability to evade immune destruction [10] . Therefore, numerous efforts have been directed to increase the efficacy of the immune system in order to enhance the anti-tumor action either by stimulation or inhibition of different molecular signals. One of the challenges in immune therapy is the understanding of the complexity of immune processes and interfering pathways that is indispensable for the development of effective drugs. Bladder cancer is a highly immunogenic tumor [11] , which can be discerned by the antitumor effects of intravesical Bacille-Calmette-Guerin immunotherapy used routinely for adjuvant intravesical treatment of non-muscle invasive bladder cancer [12] .
Checkpoint inhibitors are novel humanized antibodies. Two categories of these antibodies are manufactured. Ipilimumab is an antibody against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), while as atezolizumab (MPDL3280A) pembrolizumab and nivolumab are blockers of anti-programmed death 1/-ligand 1(PD-1/ PD-L1) receptor [13] . These drugs represent a new era in cancer therapy as durable responses have been reported with these drugs for some cancer entities (i.e. metastatic melanoma [14] ). In urological cancers, durable responses to checkpoint inhibition were detected in prostate and renal cancers [15, 16] . For metastatic bladder cancer, preliminary results have been published in several studies but robust data are still lacking [17, 18] . For this reason, we aimed to systematically review the published results on checkpoint inhibitors in metastatic bladder cancer and discuss their mechanism of action on a molecular level in order to address the question of how their clinical efficacy could be better predicted and potentially increased.
Methodology
For this systematic review, we have followed the PRISMA criteria for all available data on this topic [19] . The search was conducted via the use of electronic databases including PubMed and ASCO Meeting Library for references published between 2010 and 2015. Only full-text publications and abstracts in English language (published in citable form) were considered for analysis. The search strategy was based on the following keywords: anti CTLA-4, anti PD-L1, bladder cancer, checkpoint inhibitor, immunotherapy, atezolizumab, MPDL3280A, nivolumab, ipilimumab, pembrolizumab. A total number of 626 articles and abstracts were initially identified. The exclusion process was conducted at two stages for data not reporting on clinical application of checkpoint inhibitors in bladder cancer. Since phase III trials on checkpoint inhibitors for metastatic bladder cancer have been launched just recently, the available clinical data are based on non-randomized prospective studies. Two articles and two abstracts were eligible for final data analysis; one article and one abstract reported on updated data of the same phase I study (NCT01375842) on response to anti PD-L1 therapy [17, 20] . Another article and abstract provided data on tolerability and predictors of response to anti-CTLA-4 treatment [21, 22] . A CONSORT diagram is provided in Fig. 1 to illustrate the selection process in detail. For statistical comparison between groups, 2-sample t test was used with p value \0.05 considered as level of significant difference.
Results
Anti-PD-L1 therapy Atezolizumab (MPDL3280A) was investigated in a total of 155 patients [median age of 65.5 (36-89) years] in a phase I trial [17, 20] . Of these patients, 152 were evaluable for clinical efficacy. One hundred and twelve patients (72 %) had visceral metastasis and 141 (93 %) received at least one prior platinum-based chemotherapeutic regimen. Of these 152 patients, 76 (50 %) displayed PD-L1 positivity on tumor-infiltrating lymphocytes [as assessed by immunohistochemistry with an IHC score of 2 or 3; (2-3)], 73 (48 %) displayed an IHC score of 0-1, and three patients (2 %) had an unknown IHC assessment (see Table 1 ). Albeit being not statistically significant, a high degree of correlation between overall response rates (ORR) and PD-L1 positivity was found for patients with non-visceral metastases; the ORR was 45 % for patients with positive PD-L1 expression (34/ 76) and 14 % (10/73) for those with negative expression (45 vs 14 %; p = 0.21). In the subgroup of patients with positive PD-L1 expression, those with non-visceral metastases exhibited higher ORR compared to those with visceral metastases (82 vs 28 %; p = 0.001) (see Table 2 ).
Drug related adverse events (AE) were reported in 61 % (95/155) of any grade with fatigue and nausea being of highest frequency. Ten of the 155 patients (6 %) showed grade 3-4 AE.
Anti-CTLA4-therapy
Data on clinical response to anti CTLA-4 therapy are lacking. Only tolerability was investigated in 12 patients with localized bladder cancer (median age of 68.5 years, range 55-76). Two doses of anti CTLA-4 therapy were administrated before cystectomy. AE of any grade were recorded in 90 % (11/12) with rash and diarrhea being the most prevalent ones (both 7/12; 60 %). Four out of 12 patients (33 %) showed grade 3 AE [21] .
Discussion Prediction of response to checkpoint inhibitor therapy
The results of this review suggest that patients with PD-L1 positive expression and non-visceral metastatic disease derive the highest clinical benefit from therapy with PD-L1 inhibitors. Currently, atezolizumab (MPDL3280A) is the most promising checkpoint inhibitor in urothelial cancer with higher response rate than reported for pembrolizumab (MK-3475) [23] . No data on the clinical activity of other agents are currently available but many clinical trials are currently ongoing.
All cancer treatment modalities like chemotherapy, radiotherapy, and targeted therapies have a direct toxic effect whereas checkpoint inhibitors do not exhibit any direct cytotoxic activities on cancer cells. Their mode of action is to pave the way for the patient's immune system to increase anti-tumor activity. Therefore, it can be hypothesized that patients with an intact immune system will derive more benefit from this therapeutic approach than others. In this regard, increased expression of PD-L1 on tumor-infiltrating lymphocytes may be considered as a reflection of an intact immune system. This hypothesis is supported by data on the positive association between response rates and PD-1 positivity which was found for tumor-infiltrating lymphocytes but not for malignant cells [17] ; likewise, expression of CTLA-4 and PD-1 ligands on the cell surface was associated with increased immune activity as a response to a negative feedback loop mechanism to prevent overactivity [24, 25] . This means that increased positivity may reflect a more active immune system while impaired immunity (i.e. due to decreased performance status in case of high-volume metastatic disease) might elicit only a weak or negative expression of CTLA-4 and PD-L1. This assumption is further supported by a recent study in which PD-1 positivity on tumor-infiltrating lymphocytes was associated with prolonged overall survival in patients with urothelial carcinoma [26] . As in this study patients with non-metastatic disease showed the highest benefit, clinical activity likely depends not only on patient-centered factors (i.e. age, comorbidities) but also on tumor burden at initiation of therapy. Currently, genomic instability is considered as a separate hallmark for most cancers even for sporadic entities [27] . Response of bladder cancer to checkpoint inhibitors might be affected by the genomic pattern of the patients. For example, a factor that might predict response to checkpoint inhibitors in bladder cancer is the expression of the human epidermal growth factor-2 receptor (HER2), which was found to be overexpressed in some patients with muscle-invasive bladder cancer [28] . HER2 overexpression is associated with decreased expression of MHC-1 in breast and esophageal carcinomas [29, 30] . Theoretically, poor response could be expected in these patients while, in turn, combining checkpoint inhibitors with trastuzumab (a monoclonal HER 2 anti-body) might improve response to therapy. Yet, the identification of accurate biomarkers associated with response to treatment is in its starting phase. Petrylak et al. attempted to detect protein markers predictive for anti-PD1 therapy in bladder cancer. Lower expression of myeloid gene (i.e. Cox-2, IL8; IL1B) and decreased circulating inflammatory and tumor markers (i.e. CRP; HCG, CA19-9, CA-125) correlated with response to anti PD-1 treatment [16] . Yet, these results are thwarted by trials demonstrating a wide variability in PD-1 positivity ranging between from 2 and 47 % [31] .
The relation between bladder cancer and CTLA-4 antigen is not completely resolved [32] . In contrast to many cancers, Wang et al. [33] reported on lower frequency of CTLA-4 ?49GG genotype in bladder cancer patients. On the genetic level, investigators reported on a significant effect of anti-CTLA-4 on the expression of 289 differentially expressed genes and also identified 9 microRNAs regulating their expression [22] .
In general, anti PD-1 exhibited better tolerability than anti-CTLA-4. This might be related to the different mechanisms of immune disinhibition; anti PD-1 mainly prevent inhibition of already existing chronic immune responses while with anti CTLA-4, new auto-reactive T cells will be generated [34] .
How previous therapies might affect immune cells and subsequent responses to immunotherapy
Checkpoint inhibitors enhance indirectly the anti-tumor activity of T-cells through interrupting the inhibitory signal of CTLA-4 and PD-L1 [35] . A major step in cytotoxic T-lymphocytes (CTLs) activation is the binding of the T-cell receptor (TCR) to the antigen presented on the major histocompatibility complex 1 molecule (MHC-1) of antigen presenting cells (APCs) [36] . In the following, the T-cell activity is regulated either by stimulatory signals for further immune action, or inhibitory signals to downregulate the immune system as a protective mechanism against harmful immune overactivity. Which mechanism is active depends on which ligand binds to the TCR. Binding of B7 membrane protein of APC to CD28 receptor on activated CTLs leads to stimulatory effect [37, 38] through release of cytokines as IL-2, which increase cell proliferation. Binding of B7 to CTLA-4, a competitive analogue of CD28 results in downregulation. This immune regulatory step occurs mainly in lymphoid tissues at an early stage of the T-cell activation process as a result of a negative feedback mechanism for CD28:B7 binding. In naive T-cells, CTLA-4 are entrapped inside intracellular vesicles, and then transferred to the cell surface by exocytosis as a result of stimulatory signals elicited from CD28:B7 binding [39] . Similar to CTLA-4, PD-L1 exerts an inhibitory effect on activated T-cells. Binding of the PD-L1 ligand to its receptor on the T-cell surface results in decreased survival of T-cells and depleted production of cytokines as Interferon-c (IFN-c), IL-2 and Tumor-Necrosis-Factor (TNF). This regulatory mechanism-unlike CTLA-4-occurs at a late stage of T-cell activation and is considered as a sign of T-cell exhaustion [40] .
Identification of eligible patients for effective checkpoint inhibitor therapy is crucial for maximizing outcomes. It has to be taken into consideration that any prior treatment with impact on patient's immune status or tumor microenvironment (TME) might also affect response to checkpoint inhibitors. Understanding of how prior therapies affect the immune system will be helpful in identifying a suitable patient and preventing the administration of therapy to those who will not respond.
Cisplatin-based combination chemotherapy is widely used for patients with advanced or metastatic bladder cancer. A common side effect of chemotherapy is bone marrow suppression that decreases white blood cell production and subsequently immune cells [41] . This effect depends on the dose and duration of treatment, and is often reversible with time [42] . By contrast, some investigators have reported on the immune enhancing activity of cisplatin through increased MHC-1 expression and proliferation of effector T-cells as well as upregulation of their cytolytic activity [43] . Recently, chemotherapy was found to increase PD-L1 expression in ovarian carcinoma on an experimental level [44] , which might be explained by immune activation.
In patients with invasive bladder cancer who are unfit for surgery, external beam radiotherapy (EBRT) can be used as an alternative treatment especially in combination with chemotherapy [45] . Theoretically, the molecular changes in the TME might influence response to anti-tumor immune activity. It was suggested that radiation improves the anti-tumor immune response via different mechanisms. As the antigen presentation by APC is a key step in T-cell activation, the cytolytic effect of radiotherapy on tumor cells causes an immunogenic cell death (ICD), which differs from normal cell death in the ability to activate APCs. As a consequence, the destructed cellular particles are presented as antigens on MHC-1 [46] . In addition, the inflammatory reaction due to radiation enhances the recruitment of cytokine-mediated effector T-cells [47] . This immune-stimulatory effect of radiotherapy could be supported by the reported abscopal effect in a few patients with melanoma-a systemic effect of local radiation causing regression of distant metastasis in response to local radiotherapy [48] . On the other hand, radiotherapy was suggested to increase the recruitment of immunosuppressive cells as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) [49] . Absence of conclusive evidence on the impact of chemotherapy and radiotherapy on the activity of the immune system prior to initiation of checkpoint inhibitor therapy adds a big limitation to predict subsequent responses. A clear answer for this question can only be given within the framework of prospective studies. The available evidence, however, justifies its use as a monotherapy in the first line setting, or in combination with chemo-or radiotherapy. In fact, a very recent phase I trial reported on the synergistic effect of radiotherapy and checkpoint inhibitors in malignant melanoma [50, 51] . Furthermore, combination of both CTLA-4 and PD-L1 antibodies with radiotherapy showed promising results in experimental studies [52] . As CTLA-4 and PD-L1 inhibit the immune activity at different levels, a dual blockage might be more effective than the use of a single agent. As a monotherapy, checkpoint inhibitors displayed acceptable tolerability in bladder cancer as well as in other malignancies [53, 54] . However, combination of both anti CTLA-4 and anti PD-L1 might increase treatment-related AE as recently reported for melanoma patients [55] .
Conclusion
Although the application of checkpoint inhibitors in bladder cancer is in its starting phase, the available results suggest that patients with low-volume metastatic disease and positive PD-L1 expression will derive the highest clinical benefit. Notwithstanding, there is a high variability in response to this novel therapy. The clinical activity of these drugs might depend mainly on the status of the immune system. This could be influenced by a variety of factors like the hosts immunogenic capability, genetic mutations and prior therapeutic modalities. Investigation of these factors in already treated patients and their prospective validation will become essential to optimize outcomes.
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